Methylprednisolone

Methylprednisolone is a synthetic glucocorticoid, one of the corticosteroid hormones that mimic cortisol, the steroid the adrenal glands make naturally ^[1][2]. It is a close chemical relative of prednisolone, from which it is derived, and belongs to the pregnane class of steroids ^[1]. Like other systemic glucocorticoids it is well absorbed by mouth and is broken down in the liver ^[1][2]. It is available as the base compound for oral use and as soluble and long-acting salts for injection ^[1].

The drug was first synthesized and brought to market by the Upjohn Company and approved for medical use in the United States in 1957 ^[1]. It has since become a mainstay corticosteroid, sold as oral Medrol tablets, as the rapidly acting Solu-Medrol for intravenous or intramuscular injection, and as the depot preparation Depo-Medrol for injection into joints, lesions, or muscle ^[1]. It is now off-patent and widely available as a generic ^[1].

Methylprednisolone is used across medicine wherever powerful suppression of inflammation or immune activity is needed ^[1][2]. Common indications include serious allergic reactions and angioedema, asthma and other airway flares, rheumatic and autoimmune diseases such as lupus and rheumatoid arthritis, inflammatory bowel disease, certain blood disorders, and acute relapses of multiple sclerosis, where high-dose intravenous courses are given ^[1]. It is also used in organ transplantation to prevent or treat rejection, and glucocorticoids of this kind were adopted in the treatment of severe COVID-19 ^[1]. It works by reshaping the numbers and behavior of white blood cells and by damping down the cytokines and other chemical messengers that drive inflammation ^[1].

Methylprednisolone is a prescription-only medicine and is included on the World Health Organization's Model List of Essential Medicines ^[1]. Its side effects are those of glucocorticoids generally and grow more likely with higher doses and longer courses; they include raised blood sugar, increased vulnerability to infection, thinning of the bones, high blood pressure, mood and sleep disturbances, skin thinning, and, with prolonged use, the features of Cushing's syndrome ^[1]. Because sustained treatment suppresses the body's own adrenal hormone production, the drug is usually withdrawn gradually rather than stopped abruptly to avoid triggering adrenal insufficiency ^[1]. Its metabolism through the liver enzyme CYP3A4 makes it subject to interactions with drugs that induce or inhibit that enzyme ^[1][2].

Methylprednisolone is prescription only, and its side effects grow with dose and duration. Short courses can raise blood sugar, stir up mood or insomnia, increase appetite and irritate the stomach. Longer use risks weight gain, a rounded Cushingoid face, thinning bones, muscle weakness, cataracts, high blood pressure, easy infection, delayed healing and, rarely, avascular bone death. It suppresses the body's own steroid production, so after more than a couple of weeks it must be tapered slowly to avoid an adrenal crisis. It interacts with NSAIDs to raise ulcer risk, blunts live vaccines, and its levels shift with CYP3A4 drugs; blood thinners and diabetes medicines often need adjusting.

Methylprednisolone is a CYP3A4 substrate, so both directions of metabolic interaction occur. Strong CYP3A4 inhibitors including ketoconazole, itraconazole, clarithromycin and the boosters ritonavir and cobicistat can raise systemic exposure several fold; the documented consequence is iatrogenic Cushing syndrome with secondary adrenal suppression, reported even after a single joint injection in people on a boosted antiretroviral regimen. Inducers such as rifampin, phenytoin, carbamazepine and phenobarbital do the opposite and can leave a nominally adequate dose ineffective.

The pharmacodynamic interactions are more common. NSAIDs add to gastric mucosal injury and raise ulcer and bleeding risk. Potassium wasting diuretics and amphotericin B compound hypokalaemia. Glucose lowering drugs are antagonised, since corticosteroids raise blood glucose. Warfarin response shifts unpredictably in both directions.

At immunosuppressive doses live vaccines can replicate unchecked, and ciclosporin and methylprednisolone inhibit each other's clearance, with convulsions reported on the combination.

Checking a whole stack? Run it through interactions + stacks.

Methylprednisolone is a semisynthetic glucocorticoid created by adding a 6-alpha-methyl group to prednisolone, a modification developed by the Upjohn Company that increased anti-inflammatory potency while reducing the salt-retaining activity of the parent hormone. It was introduced in 1957, during the burst of corticosteroid innovation that followed the Nobel Prize-winning work on cortisone, and it was marketed under the Medrol name, later joined by the injectable Solu-Medrol and the long-acting depot form Depo-Medrol.

Its water-soluble succinate salt made high-dose intravenous "pulse" therapy practical, and the drug became central to the acute management of conditions from severe asthma and allergic reactions to autoimmune flares, transplant rejection, and multiple sclerosis relapses. It was tested prominently in the National Acute Spinal Cord Injury Study trials of high-dose therapy, work that shaped decades of debate over steroids in neurotrauma. Methylprednisolone appears on the World Health Organization's list of essential medicines and remains one of the most widely used corticosteroids in hospital practice.

Methylprednisolone is a workhorse of hospital medicine, the corticosteroid physicians reach for when inflammation must be brought under control quickly and decisively. Its appeal lies in a favorable balance: gram-for-gram it delivers more anti-inflammatory power than the body's own cortisol while causing far less fluid and salt retention, which makes it well suited to the intense, short bursts used in asthma attacks, multiple sclerosis relapses, and organ-transplant protocols.

The convenience of a tapering blister pack for outpatient courses and the availability of rapid intravenous and long-acting depot forms have made it exceptionally versatile across specialties. It is only fair to note that corticosteroids are powerful and blunt instruments, and prolonged use carries real risks including bone loss, elevated blood sugar, and immune suppression, so treatment is usually kept as brief as the illness allows. Used judiciously, though, methylprednisolone remains an indispensable and time-tested tool for taming an overactive immune response.